Not for distribution in the U.S. or to U.S. Newswires
VANCOUVER, British Columbia, April 23, 2019 (GLOBE NEWSWIRE) -- Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B), (“Blissco”) or the (“Company”) is a Canadian wellness cannabis brand based in British Columbia, a licensed processor, and producer of premium dried cannabis and cannabis oil and a licensed distributor of dried cannabis products. The Company is pleased to announce that it has submitted a licence amendment to Health Canada that will enable Blissco to sell cannabis oil products to provincially authorized distributors and retailers and to registered medical patients. Blissco received its oil production license in August of 2018 and since then, the company has focused on establishing the oil production processes required to meet the Health Canada regulations.
“We are delighted to have received positive certificates of analysis for two oil batches from an independent, Health Canada approved laboratory,” said Damian Kettlewell, Blissco CEO. “We have validated our internal systems and processes in preparation for the Health Canada oil sales licence inspection, expected to occur in the near future. When Blissco earns its cannabis oil sales licence we will be able to sell to approved medical clients across the country and in provinces where we have distribution and supply agreements for the adult market, currently including British Columbia, Alberta, New Brunswick and Saskatchewan.”
High-CBD and balanced CBD:THC cannabis oil products are in high demand from provincial distributors and medical clients. Blissco is well positioned to manufacture and supply these high-CBD oil products with existing supply and purchase contracts for premium cannabis and hemp.
Upon receipt of the oil sales licence, Blissco will offer the following oil products:
- Full spectrum high-CBD
- Full spectrum balanced CBD:THC
- Full spectrum high-THC
- Hemp derived high-CBD
Blissco’s CO2 extracted, full spectrum oils with pharmaceutical-grade MCT carrier oil, will be sold in 30 ml format glass bottles that feature a graduated dropper, making dosing simple and precise.
About Blissco Cannabis Corp.
Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B) is a Canadian wellness cannabis brand based in British Columbia and a multi-licensed processor, cultivator, and distributor of premium cannabis.
Blissco owns and operates an 18,000 square foot, state-of-the-art extraction, processing and cultivation facility located in Metro Vancouver, British Columbia. Blissco is supplying premium cannabis and Reserve whole flower and dried flower pre-rolls to the Canadian market with supply agreements in British Columbia, Alberta, Saskatchewan, and New Brunswick.
In support of Blissco’s global distribution strategy, the company has initiated its EU GMP certification process and has completed its first inspection by German authorities.
Learn more at blissco.com.
On Behalf of the Board of Directors
BLISSCO CANNABIS CORP.
Damian Kettlewell, CEO, Founder & Chair
For further information please contact:
1 604 484-9119
investors@blissco.com
Cautionary Statements
This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil licence and a licence to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.
The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.